Repligen (NASDAQ:RGEN) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a report published on Friday.

Several other brokerages have also recently issued reports on RGEN. Canaccord Genuity Group boosted their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday. JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $183.36.

Repligen Stock Down 2.3 %

RGEN stock opened at $158.99 on Friday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.91 billion, a price-to-earnings ratio of -429.69, a PEG ratio of 4.23 and a beta of 0.99. The business’s fifty day moving average price is $155.22 and its two-hundred day moving average price is $148.79.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. On average, equities analysts anticipate that Repligen will post 1.54 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

Several large investors have recently bought and sold shares of RGEN. GTS Securities LLC bought a new stake in shares of Repligen during the fourth quarter worth about $264,000. Gordian Capital Singapore Pte Ltd acquired a new stake in Repligen during the 4th quarter worth approximately $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Repligen by 12.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock worth $33,875,000 after acquiring an additional 26,733 shares during the last quarter. Two Sigma Advisers LP increased its position in Repligen by 6.7% in the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock valued at $19,403,000 after acquiring an additional 8,500 shares during the period. Finally, Raiffeisen Bank International AG bought a new position in shares of Repligen during the fourth quarter valued at $29,000. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.